Drug intelligence / Profile preview

STIA-1002

Development stage: Preclinical
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STIA-1002 is a monoclonal antibody developed by Staidson (Beijing) Biopharmaceutical (Staidson Hongkong) for the treatment of rheumatoid arthritis (RA). It is designed to target and neutralize tumor necrosis factor (TNF), a key pro-inflammatory cytokine that plays a central role in the pathogenesis of chronic inflammatory and autoimmune diseases. By binding to TNF, STIA-1002 inhibits the interaction of the cytokine with its cell surface receptors, thereby blocking downstream inflammatory signaling pathways. This mechanism aims to reduce joint inflammation, alleviate symptoms, and prevent structural damage in patients with RA. The drug is currently listed in Staidson's research and development pipeline.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on STIA-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STIA-1002.

Explore the full profile